Skip to main content

Table 3 Overall survival (OS) regarding different treatment regimens

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

Treatment Number of patients OS months
Range (Mean ± SD) Median
VCD 54 1–156 28.5 ± 30.5 20.3
VRD 10 3–63 27.5 ± 17.7 26.4
VTD 8 12–77 41.5 ± 23.2 44.5
Endoxan-Dexa 9 2–20 8.13 ± 6.9 5.1
  1. VCD Velcade® (bortezomib)-cyclophosphamide-dexamethasone, VRD Velcade® (bortezomib)-Revlimid® (lenalidomide)-dexamethasone, VTD Velcade® (bortezomib)-thalidomide-dexamethasone; Endoxan-Dexa endoxan-dexamethasone